Using B cells to improve recovery from acute respiratory distress syndrome (ARDS)
Official title: B cells for treatment of ARDS
Funded at Massachusetts General Hospital · NIH-11175768 · Data updated 2026-11-12
This study is looking at how special immune cells called B cells might help people recovering from acute respiratory distress syndrome (ARDS) by reducing inflammation and helping the lungs and brain heal.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $610,236 |
| NIH project number | 1R56HL175336-01 |
| Project ID | NIH-11175768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults who have experienced ARDS and are facing ongoing pulmonary or neurological issues.
✕Less likely to help
Patients who have not experienced ARDS or those with other unrelated respiratory conditions may not benefit from this research.
What this research studies
This research investigates how B cells can be used to treat patients recovering from acute respiratory distress syndrome (ARDS), particularly focusing on the pulmonary and neurological complications that can arise after the condition. The study utilizes a mouse model to explore how B cells can be administered to reduce inflammation and promote healing in the lungs and brain. By understanding how these B cells migrate to areas of injury, the research aims to develop a therapy that could restore immune balance and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly enhance recovery and reduce long-term complications for ARDS survivors.
How similar studies have gone: Previous research has shown promise in using B cell therapies for inflammatory conditions, suggesting potential success for this novel approach in ARDS.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Hanidziar, Dusan — Massachusetts General Hospital
- Study coordinator: Hanidziar, Dusan
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.